Biology of Blood and Marrow Transplantation

Slides:



Advertisements
Similar presentations
A disease risk index for patients undergoing allogeneic stem cell transplantation by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T. Ho,
Advertisements

Unbalanced recovery of regulatory and effector T cells after allogeneic stem cell transplantation contributes to chronic GVHD by Ana C. Alho, Haesook T.
Cord-Blood Hematopoietic Stem Cell Transplant Confers an Increased Risk for Human Herpesvirus-6-Associated Acute Limbic Encephalitis: A Cohort Analysis 
Follistatin and Endoglin: Potential Biomarkers of Endothelial Damage and Non-Relapse Mortality after Myeloablative Allogeneic Hematopoietic Cell Transplantation.
Immune Reconstitution after Double Umbilical Cord Blood Stem Cell Transplantation: Comparison with Unrelated Peripheral Blood Stem Cell Transplantation 
Philippe Armand, Haesook T. Kim, Johanna M. Virtanen, Riitta K
Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular.
Improved Treatment-Related Mortality and Overall Survival of Patients with Grade IV Acute GVHD in the Modern Years  Areej El-Jawahri, Shuli Li, Joseph.
Bradley W. Blaser, Haesook T. Kim, Edwin P. Alyea, Vincent T
Outcomes of Allogeneic Stem Cell Transplantation in Elderly Patients with Acute Myeloid Leukemia: A Systematic Review and Meta-analysis  Armin Rashidi,
Prediction of Veno-Occlusive Disease Using Biomarkers of Endothelial Injury  Corey Cutler, Haesook T. Kim, Shaké Ayanian, Gary Bradwin, Carolyn Revta,
by Philippe Armand, Christopher J. Gibson, Corey Cutler, Vincent T
Daniela Ion, Kristen Stevenson, Sook-Bin Woo, Vincent T
A Phase II Study of Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft- versus-Host Disease  Alex F. Herrera, Haesook T. Kim, Bhavjot Bindra,
Hematopoietic Cell Transplantation with and without Sorafenib Maintenance for Patients with FLT3-ITD Acute Myeloid Leukemia in CR1  Andrew M. Brunner,
Allogeneic Transplantation with Reduced-Intensity Conditioning for Hodgkin and non- Hodgkin Lymphoma: Importance of Histology for Outcome  Philippe Armand,
Biology of Blood and Marrow Transplantation
Phase II Trial of Tandem High-Dose Chemotherapy with Autologous Stem Cell Transplantation Followed by Reduced-Intensity Allogeneic Stem Cell Transplantation.
Outcome and Prognostic Factors for Patients Who Relapse after Allogeneic Hematopoietic Stem Cell Transplantation  Gita Thanarajasingam, Haesook T. Kim,
Nienke M. G. Rorije, Margaret M. Shea, Gowri Satyanarayana, Sarah P
Decision Analysis of Peripheral Blood versus Bone Marrow Hematopoietic Stem Cells for Allogeneic Hematopoietic Cell Transplantation  Joseph Pidala, Claudio.
Busulfan Dose Intensity and Outcomes in Reduced-Intensity Allogeneic Peripheral Blood Stem Cell Transplantation for Myelodysplastic Syndrome or Acute.
Jennifer Crombie, Laura Spring, Shuli Li, Robert J. Soiffer, Joseph H
Impact of Cytogenetics on Outcome of De Novo and Therapy-Related AML and MDS after Allogeneic Transplantation  Philippe Armand, Haesook T. Kim, Daniel.
Seroprotective Titers against 2009 H1N1 Influenza A Virus after Vaccination in Allogeneic Hematopoietic Stem Cell Transplantation Recipients  Nicolas.
Phase II Trial of Parathyroid Hormone after Double Umbilical Cord Blood Transplantation  Karen Ballen, Adam M. Mendizabal, Corey Cutler, Ioannis Politikos,
Biology of Blood and Marrow Transplantation
Oral Chronic Graft-versus-Host Disease Scoring Using the NIH Consensus Criteria  Nathaniel S. Treister, Kristen Stevenson, MS, Haesook Kim, Sook-Bin Woo,
Total Marrow Lymphoid Irradiation/Fludarabine/ Melphalan Conditioning for Allogeneic Hematopoietic Cell Transplantation  Lindsay G. Jensen, Tracey Stiller,
Phase II Trial of Reduced-Intensity Busulfan/Clofarabine Conditioning with Allogeneic Hematopoietic Stem Cell Transplantation for Patients with Acute.
NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report.
Favorable Outcomes in Patients Surviving 5 or More Years after Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies  Robert.
Absolute Lymphocyte Count Recovery after Allogeneic Hematopoietic Stem Cell Transplantation Predicts Clinical Outcome  Haesook T. Kim, Philippe Armand,
Allogeneic Hematopoietic Stem Cell Transplantation in Adult Acute Lymphocytic Leukemia: Impact of Donor Source on Survival  Priya Kumar, Todd E. Defor,
Fludarabine/Busulfan versus Fludarabine/Melphalan Conditioning in Patients Undergoing Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation.
Favorable Overall Survival with Fully Myeloablative Allogeneic Stem Cell Transplantation for Follicular Lymphoma  John Kuruvilla, Gregory Pond, Richard.
Post-Transplantation B Cell Activating Factor and B Cell Recovery before Onset of Chronic Graft-versus-Host Disease  Caron A. Jacobson, Lixian Sun, Haesook.
Efficacy of Thiotepa-Busulfan-Cyclophosphamide (TBC) Conditioning and Autologous Transplantation As Consolidation for Systemic Non-Hodgkin Lymphoma with.
An Open-Label Phase II Randomized Trial of Topical Dexamethasone and Tacrolimus Solutions for the Treatment of Oral Chronic Graft-versus-Host Disease 
Comparison of Tacrolimus and Sirolimus (Tac/Sir) versus Tacrolimus, Sirolimus, and Mini-Methotrexate (Tac/Sir/MTX) as Acute Graft-versus-Host Disease.
The Dilemma of Conditioning Intensity: When Does Myeloablative Conditioning Improve Outcomes for Allogeneic Hematopoietic Cell Transplantation?  Melhem.
Mucositis after Allogeneic Hematopoietic Stem Cell Transplantation: A Cohort Study of Methotrexate- and Non-Methotrexate-Containing Graft-versus-Host.
Allogeneic Stem Cell Transplantation for Aplastic Anemia
Clinical Endpoints in Allogeneic Hematopoietic Stem Cell Transplantation Studies: The Cost of Freedom  Haesook T. Kim, Philippe Armand  Biology of Blood.
Outcomes of Cord Blood Transplantation as Salvage Therapy after Graft Failure or Relapse after Prior Allogeneic Transplantation  Rachel B. Salit, Filippo.
Akiko M. Saito, Corey Cutler, David Zahrieh, Robert J
Merve Postalcioglu, Haesook T. Kim, Faruk Obut, Benjamin C
Low-Dose IL-2 Therapy Preferentially Improves Diversity of the Regulatory T Cell Repertoire in Patients with Refractory Chronic Graft-Versus-Host Disease 
Use of Myeloablative or Reduced Intensity Conditioning with Haploidentical Hematopoietic Cell Transplantation for Acute Leukemia and MDS is Associated.
The Impact of Geographic Proximity to Transplant Center on Outcomes after Allogeneic Hematopoietic Stem Cell Transplantation  Karim E. Abou-Nassar, Haesook.
Reduced-Intensity Conditioning Hematopoietic Stem Cell Transplantation in Patients Over 60 Years: Hematologic Malignancy Outcomes Are Not Impaired in Advanced.
Philippe Armand, MD, PhD, Haesook T
Recovery of Circulating T-Follicular Helper Cells after Hematopoietic Stem Cell Transplantation  Edouard Forcade, MD, Steven Paula, Kristen Cowens, Marta.
Karen K. Ballen, Thomas R. Spitzer, Beow Y
A Prognostic Score for Patients with Acute Leukemia or Myelodysplastic Syndromes Undergoing Allogeneic Stem Cell Transplantation  Philippe Armand, Haesook.
A Bortezomib-Based Regimen Offers Promising Survival and Graft-versus-Host Disease Prophylaxis in Myeloablative HLA-Mismatched and Unrelated Donor Transplantation:
Biology of Blood and Marrow Transplantation
John Koreth, Edwin P. Alyea, William J. Murphy, Lisbeth A. Welniak 
Reduced Intensity Conditioning for Allogeneic Hematopoietic Cell Transplantation: Current Perspectives  Brenda M. Sandmaier, Stephen Mackinnon, Richard.
Prediction and prevention of transplant-related mortality from pulmonary causes after total body irradiation and allogeneic stem cell transplantation 
Treatment versus Transplant for Challenging Hematologic Disorders
Adult Recipients of Matched Related Donor Blood Cell Transplants Given Myeloablative Regimens Including Pretransplant Antithymocyte Globulin Have Lower.
Reduced-Intensity Conditioning Stem Cell Transplantation: Comparison of Double Umbilical Cord Blood and Unrelated Donor Grafts  Yi-Bin Chen, Julie Aldridge,
Matching at Human Leukocyte Antigen-C Improved the Outcomes after Double Umbilical Cord Blood Transplantation for Recipients of Two to Four of Six Human.
Sarah Nikiforow, Haesook T
Biology of Blood and Marrow Transplantation
Futility of Relapsed Diffuse Large B Cell Lymphoma Transplantation?
In Memoriam: E. Donnall Thomas
Iron Overload in Patients with Acute Leukemia or MDS Undergoing Myeloablative Stem Cell Transplantation  Philippe Armand, Haesook T. Kim, Joanna Rhodes,
Early Clinical Predictors of Hepatic Veno-Occlusive Disease/Sinusoidal Obstruction Syndrome after Myeloablative Stem Cell Transplantation  Lindsey E.
Presentation transcript:

Biology of Blood and Marrow Transplantation Myeloablative Flu/Bu Conditioning Provides Similar Overall Survival and Lower Non- Relapse Mortality Compared to Traditional Bu/Cy or Cy/TBI in Allogeneic Transplantation  Mahasweta Gooptu, Haesook T. Kim, Vincent T. Ho, Edwin P. Alyea, John Koreth, Philippe Armand, Jerome Ritz, Robert J. Soiffer, Joseph H. Antin, Corey S. Cutler  Biology of Blood and Marrow Transplantation  Volume 23, Issue 3, (March 2017) DOI: 10.1016/j.bbmt.2016.12.177 Copyright © 2016 Terms and Conditions

Figure 1 MAC conditioning regimen 2010-August 2015: OS. Biology of Blood and Marrow Transplantation 2017 23, DOI: (10.1016/j.bbmt.2016.12.177) Copyright © 2016 Terms and Conditions

Figure 2 MAC conditioning regimen 2010-August 2015: NRM. Biology of Blood and Marrow Transplantation 2017 23, DOI: (10.1016/j.bbmt.2016.12.177) Copyright © 2016 Terms and Conditions

Feedback: Privacy Policy Feedback
Do Not Sell My Personal Information
About project: SlidePlayer Terms of Service

© 2024 SlidePlayer.com Inc. All rights reserved.